نتایج جستجو برای: mdm2 snp309

تعداد نتایج: 4579  

2009
Lukasz F. Grochola Alexei Vazquez Elisabeth E. Bond Peter Würl Helge Taubert Thomas H. Müller Arnold J. Levine Gareth L. Bond

Purpose:A regulated p53-dependent stress response is crucial in suppressing tumor formation and mediating the response to commonly used cancer therapeutics. However, little is known about the human, inherited genetics of this important signaling pathway. Experimental Design: Studies of human genetic variants in the p53 tumor suppressor gene and MDM2 oncogene have shown that single nucleotide po...

2015
Liv B. Gansmo Pål Romundstad Einar Birkeland Kristian Hveem Lars Vatten Stian Knappskog Per Eystein Lønning

The MDM4 protein plays an important part in the negative regulation of the tumor suppressor p53 through its interaction with MDM2. In line with this, MDM4 amplification has been observed in several tumor forms. A polymorphism (rs4245739 A>C; SNP34091) in the MDM4 3' untranslated region has been reported to create a target site for hsa-miR-191, resulting in decreased MDM4 mRNA levels. In this po...

2017
Siqian Lu Wenru Tang Ying Luo

Objective:The 309 T/G polymorphism of murine double minute 2 (MDM2) gene is associated with acute myeloid leukemia, but conflicting results have been reported. In this study, we performed a meta-analysis to estimate the association between MDM2 309 T/G polymorphism and acute myeloid leukemia risk. Methods: Electronic search of PubMed was conducted to select case-control studies that contain ava...

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه گیلان - دانشکده علوم پایه 1390

سقط خودبخودی را ختم حاملگی قبل از هفته بیستم حاملگی یا تولد نوزادی با وزن کمتر از 500گرم تعریف می کنند. از جمله فاکتورهای شناسایی شده در سقط، آنومالی های کروموزومی والدین، فاکتورهای ایمونولوژیک، بی نظمی های اندوکرین، ناهنجاری های رحمی، عفونت ها، فاکتور های محیطی و ... را می توان نام برد که تقریبا? در 50% سقط ها مشاهده می شوند. علاوه بر این فاکتورها، پلی مورفیسم های ژنی از فاکتورهای موثر در افزا...

2014
Stian Knappskog Liv B. Gansmo Khadizha Dibirova Andres Metspalu Cezary Cybulski Paolo Peterlongo Lauri Aaltonen Lars Vatten Pål Romundstad Kristian Hveem Peter Devilee Gareth D. Evans Dongxin Lin Guy Van Camp Vangelis G. Manolopoulos Ana Osorio Lili Milani Tayfun Ozcelik Pierre Zalloua Francis Mouzaya Elena Bliznetz Elena Balanovska Elvira Pocheshkova Vaidutis Kučinskas Lubov Atramentova Pagbajabyn Nymadawa Konstantin Titov Maria Lavryashina Yuldash Yusupov Natalia Bogdanova Sergey Koshel Jorge Zamora David C. Wedge Deborah Charlesworth Thilo Dörk Oleg Balanovsky Per E. Lønning

The MDM2 promoter SNP285C is located on the SNP309G allele. While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer. Assessing SNP285 and 309 genotypes across 25 different ethnic populations (>10.000 individuals), the incidence of SNP285C was 6-8% across European populations ex...

2010
Sean M. Post Vinod Pant Hussein Abbas Alfonso Quintás-Cardama

A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective analyses involving a wide variety of human malignancies have been reported, showing conflicting resu...

2016
Liv B. Gansmo Lars Vatten Pål Romundstad Kristian Hveem Bríd M. Ryan Curtis C. Harris Stian Knappskog Per E. Lønning

The MDM2 promoter region contains several polymorphisms, some of which have been associated with MDM2 expression, cancer risk and age at cancer onset. del1518 (rs3730485) is an indel polymorphism residing in the MDM2 promoter P1 and is in almost complete linkage disequilibrium with the MDM2 promoter P2 polymorphism SNP309T>G (rs2279744). Cancer risk assessments of del1518 have previously been c...

2011
Ranjan Chrisanthar Stian Knappskog Erik Løkkevik Gun Anker Bjørn Østenstad Steinar Lundgren Terje Risberg Ingvil Mjaaland Gudbrand Skjønsberg Turid Aas Ellen Schlichting Hans E. Fjösne Arne Nysted Johan Richard Lillehaug Per Eystein Lønning

BACKGROUND TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wild-type p53 protein activity. Here, we explored the predictive and prognostic value of TP53 and CHEK2 mutation status together with MDM2 SNP309 genotype in stage III br...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید